Management strategy of patients with chronic myeloid leukemia in chronic phase who failed to response to imatinib – Kraków Haematology Clinic experience
Journal Title: OncoReview - Year 2011, Vol 1, Issue 3
Abstract
Introduction: Tyrosine kinase inhibitors eliminate chronic myeloid leukemia cells in a targeted way. The resistance to this therapy was the cause of development of treatment recommendations and drugs of second and subsequent generations. The management strategy in case of resistance can vary and depends largely on the experience of the treating center.Aim : A retrospective analysis of second line treatment results of patients with chronic myeloid leukemia in chronic phase showing different intensity of resistance to first line treatment with imatinib.Materials and methods: 73 patients at the age of 21–80 years were when received second line treatment between 2001 to 2011. Diagnostic tests were performed to control the course of therapy according to the recommendations of EL N.Results: The worst prognosis and treatment results have been reported in patients who, during first line treatment did not achieved or lost complete hematologic response. Prognosis in patients with suboptimal response was better than among patients with primary or secondary resistance. Patients who achieved a major molecular response until 18 months after implementation of first line therapy with imatinib progressed significantly less frequently (2.8% vs 14.1%; p=0.025).Conclusions: The chances of a good response to second line therapy decreases when the intensity of resistance to first line treatment, and are greatest in those with suboptimal response. Systematic monitoring of treatment may identify a group of patients who most benefit from early treatment modification.
Authors and Affiliations
Tomasz Sacha, Kajetana Foryciarz, Izabela Florek, Sylwia Czekalska, Magdalena Zawada, Dorota Cwynar, Małgorzata Jakóbczyk, Aleksander Skotnicki
Keywords
Related Articles
- EP ID EP53108
- DOI -
- Views 206
- Downloads 0
Późny nawrót przewlekłej białaczki szpikowej po alogenicznym przeszczepieniu komórek macierzystych - opis przypadku
Przewlekła białaczka szpikowa obecnie w większości przypadków jest chorobą dobrze poddającą leczeniu inhibitorami kinazy tyrozynowej. Nadal jednak jedyną procedurą leczniczą dającą możliwość wyleczenia jest aloprzeszczep...
Therapeutic rehabilitation of cancer patients. Why and what for?
Types of oncological rehabilitation and its objectives are described. It includes information on many manifestations of oncological diseases that an internist has to deal with, which are conditioned not only by the oncol...
Effective treatment of severe hypertensive crisis in 2-year-old child with neuroblastoma
We describe a case of a 2-year-old boy with neuroblastoma and high catecholamine levels which developed a severe hypertensive crisis. An oral propranolol and oral angiotensin-converting enzyme inhibitor were used with a...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Nasopharyngeal carcinoma – treatment possibilities in patients with primary metastatic carcinoma
This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted ther...